Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

  1. Usmani, S.Z.
  2. Quach, H.
  3. Mateos, M.-V.
  4. Landgren, O.
  5. Leleu, X.
  6. Siegel, D.
  7. Weisel, K.
  8. Shu, X.
  9. Li, C.
  10. Dimopoulos, M.
Journal:
Blood Advances

ISSN: 2473-9537 2473-9529

Year of publication: 2023

Volume: 7

Issue: 14

Pages: 3739-3748

Type: Article

DOI: 10.1182/BLOODADVANCES.2023010026 GOOGLE SCHOLAR lock_openOpen access editor